Navigation Links
Researchers find potential target for drug to treat allergic asthma
Date:3/5/2014

COLUMBUS, Ohio An enzyme that helps maintain immune system function by "throwing away" a specific protein has a vital role in controlling symptoms of allergic asthma, new research in mice suggests.

The finding suggests that this enzyme, called Cbl-b, could be a target for drugs used to treat allergic asthma and other autoimmune disorders.

This new study, led by Ohio State University researchers, is the first to link Cbl-b to allergic asthma in an animal model.

The findings parallel results from a 2012 Yale study in humans, which suggested that a mutation in the gene that produces Cbl-b was associated with higher risk for asthma in children. Other studies have suggested that inhibiting Cbl-b activity could reduce tumors and lower chances for cancer to spread.

Based on this assortment of findings, scientists believe Cbl-b could be manipulated in different ways depending on the disorder in question. Its activity could be elevated to keep excessive inflammation in check in people with allergic asthma, or it could be inhibited to treat cancer.

"We believe we have found one of the key molecules that can modulate the immune response," said Jian Zhang, associate professor of microbial infection and immunity at Ohio State and senior author of the study. "We can use this basic knowledge to try to find small molecules that can modify Cbl-b's function and use this to treat human diseases that include autoimmunity, asthma and tumors."

Allergic asthma is the most common form of asthma and is triggered by inhaling such allergens as dust mites, pet dander, pollen or mold, leading to inflamed and swollen airways of the lungs, according to the American Academy of Allergy Asthma & Immunology.

The Ohio State study is published in the current issue of the journal Cell Reports.

In this work, mice that are models for allergic asthma were injected with a substance that provoked an allergic response.
'/>"/>

Contact: Jian Zhang
Jian.Zhang@osumc.edu
614-292-9447
Ohio State University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Dartmouth researchers find promising results with local hyperthermia of tumors
2. Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer
3. Researchers reveal the dual role of brain glycogen
4. Montreal researchers find a link between pollutants and certain complications of obesity
5. CNIO researchers discover new strategies for the treatment of psoriasis
6. Researchers trap moths with plant-produced sex pheromone
7. Researchers generate new neurons in brains, spinal cords of living adult mammals
8. Researchers at LSTM crack the genetic secret of mosquito resistance to DDT and ITNs
9. McMaster researchers discover secret of bowel movement
10. Researchers have identified a novel immunological mechanism of great importance for vaccine developm
11. Researchers pinpoint brain region essential for social memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... If grandma seems to forget things, will she end up ... few symptoms that may signal which 70-year-olds risk developing dementia. ... Academy at the University of Gothenburg, Sweden. Several of ... developing dementia do not seem to work any longer. The ...
... in Spanish . , DNA-Prokids ( http://www.dna-prokids.org ... using genetic identification of victims and their relatives, was officially ... (UGR) headquarters, in Spain. Traffic in human beings is ... beginning of the 21st century. According to data from the ...
... Iowa -- Researchers at Iowa State University have discovered ... plant growth. , Yanhai Yin, an assistant professor in ... a plant hormone called brassinosteroids. The hormone controls the ... major impact on how large the plant grows, says ...
Cached Biology News:Early identification of dementia increasingly difficult 2DNA-Prokids: Genetic identification against traffic in human beings 2ISU researcher identifies genetic pathway responsible for much of plant growth 2
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ... low. The only negative is the housing market remaining ...
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... WOODLANDS, Texas, Oct. 4 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... Lexicon,s president and chief executive officer, will present,at the ... California,on Thursday, October 11, 2007 at 11:00 a.m. Pacific ... be accessed on its,corporate website at http://www.lexpharma.com . ...
... In conjunction with,its third quarter 2007 earnings release (expected ... (NYSE: CVD ) is pleased to invite you to,listen ... over the Internet on Thursday, October 25 at 9:00 a.m. ... Webcast and Slide Presentation When: October 25, ...
... VRUS ) has entered into a working capital loan ... and conditions of,the agreement, Horizon will advance $10 million ... may receive a second loan of $10 million,by March ... by November 30, 2008,provided conditions precedent to making the ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
...
Biology Products: